TY - JOUR
T1 - Topical timolol in dermatology
T2 - infantile haemangiomas and beyond
AU - Alzaid, M.
AU - Al-Naseem, A.
AU - Al-Niaimi, F.
AU - Ali, F. R.
N1 - © 2021 British Association of Dermatologists.
PY - 2022/5
Y1 - 2022/5
N2 - Timolol, a nonselective β-adrenergic receptor blocker, is well-tolerated and is becoming increasingly popular in dermatology, especially in the management of infantile haemangioma (IH). Its effects are mainly due to vasoconstriction, inhibition of angiogenesis and keratinocyte migration promotion for re-epithelialization and wound healing. We review the evidence behind the use of timolol in several dermatological conditions including IH, pyogenic granulomas, Kaposi sarcoma, chronic wound healing, postsurgical wounds, acne vulgaris, rosacea, eczema and red scrotum syndrome.
AB - Timolol, a nonselective β-adrenergic receptor blocker, is well-tolerated and is becoming increasingly popular in dermatology, especially in the management of infantile haemangioma (IH). Its effects are mainly due to vasoconstriction, inhibition of angiogenesis and keratinocyte migration promotion for re-epithelialization and wound healing. We review the evidence behind the use of timolol in several dermatological conditions including IH, pyogenic granulomas, Kaposi sarcoma, chronic wound healing, postsurgical wounds, acne vulgaris, rosacea, eczema and red scrotum syndrome.
UR - http://www.scopus.com/inward/record.url?scp=85122738452&partnerID=8YFLogxK
U2 - 10.1111/ced.15021
DO - 10.1111/ced.15021
M3 - Review article
C2 - 34798680
SN - 0307-6938
VL - 47
SP - 819
EP - 832
JO - Clinical and Experimental Dermatology
JF - Clinical and Experimental Dermatology
IS - 5
ER -